Nuclear Medicine and Biology
Volume 34, Issue 3 , Pages 325-329, April 2007

Effective specific activities determined by scintillation proximity counting for production runs of [18F]FES and 4F-M[18F]FES

Sherbrooke Molecular Imaging Center (CIMS), Université de Sherbrooke, Sherbrooke, Québec, Canada J1H 5N4

Received 29 September 2006; received in revised form 1 December 2006; accepted 2 January 2007.

Abstract 

Introduction

16α-[18F]Fluoro-17β-estradiol ([18F]FES) and various derivatives can be used to image noninvasively the expression of estrogen receptors in breast cancer. A high specific activity is required for successful visualization of ER expression in vivo, particularly for small animal imaging. We describe a simple method for effective specific activity (ESA) measurements of ER-binding ligands.

Methods

Scintillator-coated polystyrene microplates (FlashPlate) were coated with purified ER of the alpha subtype. [18F]FES and 4-fluoro-11β-methoxy-16α-[18F]fluoroestradiol (4F-M[18F]FES) were prepared by stereoselective opening of their respective cyclic sulfate precursors. After decay of the radioactivity, samples at various dilutions were put in the wells of the FlashPlate along with buffer and [3H]estradiol. On the same FlashPlate, nonradioactive estradiol was placed at concentrations ranging from 10−11 to 10−6 M to provide a standard competition curve.

Results

The average effective specific activities of different batches of [18F]FES and 4F-M[18F]FES were 1169 (range, 49–6251) and 4695 (range, 413–15,261) Ci/mmol, respectively.

Conclusion

Scintillation proximity technology allows for simple and reproducible measurements of the ESA of receptor-binding radiopharmaceutical for which purified receptors are available.

Keywords: [18F]Fluoroestradiol, 4-Fluoro-11β-methoxy-16α-[18F]fluoroestradiol, Estrogen receptors, Breast cancer, Specific activity, Positron emission tomography, Receptor binding

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0969-8051(07)00008-X

doi:10.1016/j.nucmedbio.2007.01.001

Nuclear Medicine and Biology
Volume 34, Issue 3 , Pages 325-329, April 2007